Augmentation (pharmacology)

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Augmentation, in the context of the pharmacological management of psychiatry, refers to the combination of two or more drugs to achieve better treatment results. Examples include:

Prescribing an atypical antipsychotic when someone is already taking a selective serotonin reuptake inhibitor for the treatment of depression.^[1]
Prescribing estrogen for someone already being treated with antipsychotics for the management of schizophrenia.^[2]
Giving an adenosine A2A receptor antagonist on top of existing treatment for Parkinson's disease.^[3]

In pharmacology, the term is occasionally used to describe treatments that increase (augment) the concentration of some substance in the body. This might be done when someone is deficient in a hormone, enzyme, or other endogenous substance. For example:

Use of DDCIs in addition to L-DOPA, to reduce conversion of L-DOPA outside the brain.
To give α1 antitrypsin to someone with alpha 1-antitrypsin deficiency.^[4]

References

^ Wright, BM; Eiland EH, 3rd; Lorenz, R (March 2013). "Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature". Pharmacotherapy. 33 (3): 344–59. doi:10.1002/phar.1204. PMID 23456734. S2CID 2421659.{{cite journal}}: CS1 maint: numeric names: authors list (link)
^ Begemann, MJ; Dekker, CF; van Lunenburg, M; Sommer, IE (November 2012). "Estrogen augmentation in schizophrenia: a quantitative review of current evidence". Schizophrenia Research. 141 (2–3): 179–84. doi:10.1016/j.schres.2012.08.016. PMID 22998932. S2CID 40584474.
^ Zhu, C; Wang, G; Li, J; Chen, L; Wang, C; Wang, Y; Lin, P; Ran, H (November 2014). "Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis". Neurological Research. 36 (11): 1028–34. doi:10.1179/1743132814y.0000000375. PMID 24725292. S2CID 206852879.
^ Campos, MA; Lascano, J (October 2014). "α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy". Therapeutic Advances in Respiratory Disease. 8 (5): 150–61. doi:10.1177/1753465814542243. PMID 25013223. S2CID 32383294.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[1] Wright, BM; Eiland EH, 3rd; Lorenz, R (March 2013). "Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature". Pharmacotherapy. 33 (3): 344–59. doi:10.1002/phar.1204. PMID 23456734. S2CID 2421659.{{cite journal}}: CS1 maint: numeric names: authors list (link)

[2] Begemann, MJ; Dekker, CF; van Lunenburg, M; Sommer, IE (November 2012). "Estrogen augmentation in schizophrenia: a quantitative review of current evidence". Schizophrenia Research. 141 (2–3): 179–84. doi:10.1016/j.schres.2012.08.016. PMID 22998932. S2CID 40584474.

[3] Zhu, C; Wang, G; Li, J; Chen, L; Wang, C; Wang, Y; Lin, P; Ran, H (November 2014). "Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis". Neurological Research. 36 (11): 1028–34. doi:10.1179/1743132814y.0000000375. PMID 24725292. S2CID 206852879.

[4] Campos, MA; Lascano, J (October 2014). "α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy". Therapeutic Advances in Respiratory Disease. 8 (5): 150–61. doi:10.1177/1753465814542243. PMID 25013223. S2CID 32383294.

[1]

[2]

[3]

[4]